PL-9643: a melanocortin eye drop for dry eye disease

The system's quieting signal, delivered by drop — the same peptide logic, asked only to calm an eye.

PL-9643 takes the melanocortin system somewhere unexpected: the eye. It began as one of Palatin Technologies' investigational melanocortin agonists — this one an eye drop fordry eye disease, and like PL-8177 in the gut, it is built on the system's anti-inflammatory arm rather than its pigment or appetite roles.^[1] Unlike PL-8177, which is tuned to MC1R alone, PL-9643 is apan-agonist: it activates every melanocortin receptor except the adrenal MC2R, on the reasoning that the eye's anti-inflammatory biology runs through more than one of them.^[1][7]

Calming the surface, not just wetting it

Dry eye disease is not only a lubrication problem; a large part of it isinflammation of the ocular surface that becomes self-sustaining. PL-9643 activates melanocortin receptors on the eye to dampen that inflammation and push it toward resolution — the same broad biology that makes α-MSH a natural anti-inflammatory signal, applied topically. That mechanism is different both from artificial tears, which lubricate, and from broad immunosuppressants, which blunt immunity generally. The inflammation page explains why melanocortin agonists do not merely switch inflammation off but help tissue return to baseline.

Why the eye is a natural home for this biology

The eye is one of the body's immune-privileged sites, and α-MSH is part of how it stays that way: the peptide is present in the fluid inside the eye, where it helps keep immune cells from mounting the kind of response that would damage the retina. In a mouse model of autoimmune uveitis, α-MSH and a melanocortin pan-agonist suppressed the disease and preserved the retina, an MC1R-only agonist did so only temporarily, and agonists lacking MC5R activity did not — which is why the receptor that matters for ocular inflammation appears to be MC1R and MC5R together, and why a pan-agonist rather than a selective one was chosen for the eye.^[7] On the ocular surface itself, α-MSH protects corneal epithelial cells in a rat model of dry eye and in human cells under the hyperosmolar stress that characterises the disease,^[8] and in people with dry eye the levels of α-MSH and other neuropeptides in tears are altered and track with the severity of their symptoms.^[9] The pieces were in place before the drug was.

The Phase 2 lesson

PL-9643's Phase 2 trial is worth knowing about because it shaped everything after it. In a 12-week, placebo-controlled study of 160 patients dosed three times a day, the drop did not beat vehicle on its two primary endpoints — corneal staining and ocular discomfort — in the overall population. But in the 53 patients with moderate-to-severe disease it improved several objective signs, including corneal and conjunctival staining and tear break-up time, and it produced no drug-related adverse events or discontinuations.^[1] That is the pattern of a drug whose effect is real but small relative to the noise of a mild population, and the Phase 3 programme was designed around it: moderate-to-severe patients, a vehicle run-in to settle the placebo response, and endpoints chosen from the subgroup signals.

The Phase 3 result

PL-9643's pivotal trial, MELODY-1, enrolled 575 patients with moderate-to-severe dry eye at US sites, with a four-week run-in followed by twelve weeks of treatment. It met its co-primary symptom endpoint of ocular pain (P<0.025) along with several secondary symptom endpoints, with symptom relief emerging by week 2 and continuing to build through 12 weeks — and it did so withfewer ocular adverse events than the vehicle control (5.6% against 6.3%) and fewer discontinuations.^[2] It did not, however, meet the other co-primary endpoint — a sign of disease (conjunctival lissamine green staining), the objective, physician-graded measure that dry-eye drugs have long found hardest to move; secondary sign endpoints trended in the right direction without reaching significance.^[2] Updated analyses presented in 2025 found six of thirteen symptom endpoints statistically significant, and a responder analysis in which a share of patients reached complete resolution of symptoms, a result the company has stressed no approved dry-eye therapy has shown.^[3]Independent coverage framed it as a promising, potentially first-in-class approach.^[5]

Why signs are hard matters for reading the result. Dry-eye regulators in the United States have historically wanted a drug to improve both what the patient feels and what the clinician measures, and the two often move independently: staining scores are variable, fluctuate with the weather and the examiner, and have sunk many drugs that patients said helped. The FDA has since confirmed that the design and endpoints of the remaining two trials, MELODY-2 and MELODY-3, are acceptable; each is built to evaluate both the signs and the symptoms of the disease — the fuller bar a dry-eye drug must clear.^[4]

Where the programme stands

The programme has changed hands. Palatin, refocusing on its melanocortin obesity assets, sublicensed PL-9643 for dry eye to Altanispac Labs in early 2026, which is now responsible for the remaining Phase 3 trials; their start depends on funding.^[6] The pipeline page tracks it as a Phase 3 asset, which is accurate for the stage reached, with the honest caveat that the next trial has not yet begun.

The honest bottom line

PL-9643 is investigational, and a single positive symptom trial is a milestone, not an approval — the remaining MELODY studies still have to deliver, and on signs as well as symptoms. But it is a striking demonstration of the melanocortin system's reach: the same anti-inflammatory signalling behind pigment biology and gut disease, formulated as an eye drop and aimed at a tissue the system already helps keep quiet. For the underlying biology, see α-MSH and the anti-inflammatory arm; for the wider landscape, see the melanocortin pipeline.